Mianserin Viatris (Mianserin Hydrochloride)

Mianserin, the active ingredient in Mianserin Viatris, is a tetracyclic antidepressant presented as an oral tablet for systemic use. It is indicated for the treatment of major depressive disorder in adult patients, helping to improve mood and functional capacity.

GNH USA supplies Mianserin Viatris as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide. The product is manufactured for the EU market and meets European pharmacopoeial specifications.

Mianserin is a tetracyclic antidepressant used primarily in the management of depressive disorders.

- Major depressive disorder: reduces depressive symptoms and improves overall mood in adult patients. - Anxiety symptoms associated with depression: may alleviate excessive worry and tension. - Insomnia linked to depressive illness: can improve sleep quality by its sedative properties.

Mianserin may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dry mouth: reduced salivation leading to discomfort. - Sedation or drowsiness: increased sleepiness, especially at treatment initiation. - Weight gain: gradual increase in body weight. - Constipation: slowed gastrointestinal motility. - Dizziness: sensation of light‑headedness. - Increased appetite: heightened desire for food.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells. - Seizures: risk of convulsive episodes. - Cardiac arrhythmia: irregular heart rhythm, particularly in patients with pre‑existing heart disease. - Severe hypotension: marked drop in blood pressure. - Suicidal ideation: emergence of thoughts of self‑harm. - Blood dyscrasias: abnormal blood cell counts.

Before initiating therapy with Mianserin, several safety considerations should be observed.

- Monitor blood pressure: watch for hypotensive episodes, especially when standing. - Assess for suicidal thoughts: evaluate mood changes during the first weeks of treatment. - Caution in hepatic impairment: dose adjustments may be required. - Avoid abrupt discontinuation: taper gradually to reduce withdrawal symptoms. - Use cautiously in the elderly: increased sensitivity to sedation and orthostatic hypotension. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Mianserin can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe hypertensive crisis. - Selective serotonin reuptake inhibitors (SSRIs): potential for serotonin syndrome. - CNS depressants (e.g., benzodiazepines, barbiturates): additive sedation. - Antihypertensive agents: may cause excessive blood‑pressure lowering. - Alcohol: enhances sedative effects and orthostatic hypotension.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, quinidine): may increase Mianserin plasma levels. - Anticholinergic drugs: heightened anticholinergic burden. - Other antidepressants (e.g., tricyclics): overlapping side‑effect profiles. - Antihistamines: increased drowsiness. - Lithium: possible alteration of lithium serum concentrations.